Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
Deng S, Derebail S, Weiler VJ, Fong Ng J, Maroto-Martin E, Chatterjee M, Giorgetti G, Chakraborty C, Kalhotra P, Du T, Yao Y, Prabhala RH, Shammas MA, Gulla A, Aktas Samur A, Samur MK, Qiu L, Anderson KC, Fulciniti M, Munshi NC.
Deng S, et al. Among authors: anderson kc.
Blood Adv. 2024 Jun 11:bloodadvances.2023012298. doi: 10.1182/bloodadvances.2023012298. Online ahead of print.
Blood Adv. 2024.
PMID: 38861273